Gliadel Marketing For Newly-Diagnosed Glioma Will Highlight Survival Benefit
This article was originally published in The Gray Sheet
Executive Summary
Guilford Pharmaceuticals' marketing of Gliadel Wafer for use in patients undergoing surgery for newly-diagnosed malignant glioma will highlight survival benefit, the company said after receiving the supplemental indication
You may also be interested in...
Guilford Gliadel Wafer Initial Surgery Indication To Launch In First Quarter
Guilford Pharmaceuticals anticipates approval of Gliadel Wafer for newly diagnosed malignant glioma by the end of March
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.